MedTrace Logo

GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose

NCT01079624 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2010-03-03

No results posted yet for this study

Summary

Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, insulin release and glucose disposal in the body. The hypothesis is that incretin hormones not only stimulate insulin release but also inhibits gastric emptying. This effect can be utilized for further drug development.

Conditions

  • Physiology
  • Gastroenterology
  • Endocrinology

Interventions

OTHER

Glucose-insulinotropic peptide, Glucagon-like peptide-1

GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min

Sponsors & Collaborators

  • Karolinska Institutet

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • Uppsala University

    lead OTHER

Principal Investigators

  • Per M Hellstrom, MD, PhD · Karolinska Institutet, Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-01-31
Completion
2009-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079624 on ClinicalTrials.gov